durvalumab subcutaneous (MEDI4736 SC)
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 07, 2024
ESMO 2024: Treatment of uHCC : Episode 2: Treatment Decisions Based on BLCL Stage
(OncLive)
- "Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions."
Video
1 to 1
Of
1
Go to page
1